Granules India shares rise as board approves fundraising of up to ₹1,462.5 crore; all you need to know

The company plans to raise funds through the issuance of up to 2.5 crore convertible warrants at a price of ₹585 per warrant, aggregating up to ₹1,462.50 crore, on a preferential basis to promoter group members and non-promoter investors. The cash-paid warrants can be converted into fully paid equity shares of ₹1 each, in one or more tranches, within 18 months from the allotment date.

Further, Granules India plans to raise up to ₹300 crore through the preferential issuance of 5,128,205 fully paid equity shares at a price of ₹585 per share to various non-promoter investors.

Following the development, Granules India shares were trading at ₹603.65 apiece on NSE, gaining 0.48%.

On Monday, the drug firm’s wholly owned subsidiary, Granules Pharmaceuticals Inc., received approval from the US health regulator to market a generic medication for attention deficit hyperactivity disorder.

Granules India share price

In the last five trading sessions, Granules India shares have jumped 6%. Over a month’s time, the stock has risen more than 13%, while in the last six months, the shares have surged 21.6%. Since the beginning of 2025, the stock has risen 1.19%.

Shares of the firm had touched their one-year high of ₹621.10 apiece on January 7, 2025, while their 52-week low of ₹422 was hit on April 9, 2025.

The company has a market capitalisation of ₹14,674.18 crore.

Granules India Q2 earnings

Granules India's net profit gained 35% year-on-year (YoY) to ₹131 crore as compared to ₹97.2 crore in the same period last year.

Its revenue grew 34.2% to ₹1,297 crore from ₹966.6 crore a year ago, while EBITDA increased 37% to ₹278 crore from ₹203.4 crore YoY.

The company's EBITDA margin improved marginally to 21.4%, up from 21% in the year-ago quarter.